Integrative Single-Cell and Bulk RNA Sequencing Identifies a Glycolysis-Related Prognostic Signature for Predicting Prognosis in Pancreatic Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115105 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nan Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Glycolysis, Single-Cell Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province, Heilongjiang Touyan Innovation Team Program, Scientific research funds of Heilongjiang pro-vincial scientific research institutes.
Abstract (Originalsprache)
Alterations in glycolysis play a crucial role in cancer cells, influencing tumor aggressiveness and therapeutic effect, particularly in pancreatic adenocarcinoma (PAAD). However, the specific glycolysis-related genes involved in PAAD progression remain poorly understood. This study established glycolysis-related molecular subtypes with distinct survival outcomes using TCGA datasets. The favorable prognosis subtype exhibited enhanced immune infiltration and an activated tumor microenvironment. A glycolysis prognostic model effectively predicted PAAD survival, correlating with global glycolytic pathways, and AUCell evaluated neutrophil communication networks of models. Functional validation demonstrated that ENO1/PGM2L1 co-expression promoted tumor proliferation, migration, invasion, and glycolytic flux in vitro, while accelerating xenograft growth in vivo. Conversely, their knockdown suppressed malignancy. Our study demonstrated that the glycolytic prognostic risk model serves as a reliable tool for prognosis and prediction of PAAD progression. ENO1 and PGM2L1 emerge as key risk factors promoting the malignant progression of PAAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
- Key Laboratory of Preservation of Human Genetics Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin 150081, China.
- State Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin 150081, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
- Heilongjiang Touyan Innovation Team Program, Scientific research funds of Heilongjiang pro-vincial scientific research institutes
- Heilongjiang Province’s Discipline Collaborative Innovation
- Heilongjiang Touyan Innovation Team Program
Zitieren
APA
Wu, N., Zhou, C., Yan, X., Liu, Z., Jiang, R., Luo, Y., Jiang, P., Mu, Y., Xiao, S., Huang, X., Zhou, Y., Sun, D., & Jin, Y. (2025). Integrative Single-Cell and Bulk RNA Sequencing Identifies a Glycolysis-Related Prognostic Signature for Predicting Prognosis in Pancreatic Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115105
Vancouver
Wu N, Zhou C, Yan X, Liu Z, Jiang R, Luo Y, et al. Integrative Single-Cell and Bulk RNA Sequencing Identifies a Glycolysis-Related Prognostic Signature for Predicting Prognosis in Pancreatic Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115105
BibTeX
@article{Wu2025,
author = {Wu, Nan and Zhou, Chong and Yan, Xu and Liu, Ziang and Jiang, Ruohan and Luo, Yuzhou and Jiang, Ping and Mu, Yu and Xiao, Shan and Huang, Xien and Zhou, Yunzhen and Sun, Donglin and Jin, Yan},
title = {Integrative Single-Cell and Bulk RNA Sequencing Identifies a Glycolysis-Related Prognostic Signature for Predicting Prognosis in Pancreatic Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115105}
}
EUVIMED